Table 2.

Normal IGF-1 or glucose-suppressed GH levels at weeks 0 and 24 or at early termination

	Switch patients (n = 33)	Other patients (n = 26)
Week 0, n (%)
Normal IGF-1 and GH < 1 μg/L	19/30 (63.3)	1/25 (4.0)
Normal IGF-1 and GH > 1 μg/L	6/30 (20.0)	3/25 (12.0)
Elevated IGF-1 and GH < 1 μg/L	2/30 (6.7)	2/25 (8.0)
Elevated IGF-1 and GH > 1 μg/L	3/30 (10.0)	19/25 (76.0)
Week 24 or early termination, n (%)
Normal IGF-1 and GH < 1 μg/L	19/26 (73.1)	7/23 (30.4)*
Normal IGF-1 and GH > 1 μg/L	5/26 (19.2)	3/23 (13.0)
Elevated IGF-1 and GH < 1 μg/L	1/26 (3.8)	2/23 (8.7)
Elevated IGF-1 and GH > 1 μg/L	1/26 (3.8)	11/23 (47.8)

Glucose-suppressed GH levels were not obtained in diabetic patients and were not obtained in all of the early termination patients

* P = 0.0143 versus week 0